Sana Biotechnology Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance as of December 31, 2023 | 197,857 | $20 | $1,625,637 | $(60) | $(1,338,091) | $287,506 |
| Issuance of common stock from at the market offering, net of issuance costs of $113 | 150 | - | 1,037 | - | - | 1,037 |
| Issuance of common stock from follow-on offering and accompanying pre-funded warrants, net of issuance costs of $9,741 | 21,773 | 2 | 180,006 | - | - | 180,008 |
| Vesting of restricted stock | 386 | - | - | - | - | - |
| Exercise of stock options | 1,120 | - | 4,929 | - | - | 4,929 |
| Stock-based compensation expense | - | - | 9,092 | - | - | 9,092 |
| Unrealized gain on marketable securities, net | - | - | - | 45 | - | 45 |
| Net loss | - | - | - | - | (107,475) | (107,475) |
| Balance as of March 31, 2024 | 221,286 | 22 | 1,820,701 | (15) | (1,445,566) | 375,142 |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance as of December 31, 2022 | 191,022 | $19 | $1,558,459 | $(4,327) | $(1,054,836) | $499,315 |
| Fees incurred related to issuance of common stock from at the market offering | - | - | (200) | - | - | (200) |
| Vesting of restricted stock | 154 | - | - | - | - | - |
| Exercise of stock options | 233 | - | 331 | - | - | 331 |
| Stock-based compensation expense | - | - | 8,751 | - | - | 8,751 |
| Unrealized gain on marketable securities, net | - | - | - | 2,188 | - | 2,188 |
| Net loss | - | - | - | - | (82,123) | (82,123) |
| Balance as of March 31, 2023 | 191,409 | $19 | $1,567,341 | $(2,139) | $(1,136,959) | $428,262 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.